Artificial pancreas goes outpatient: A new diabetes ecosystem

Journal of Diabetes Science and Technology

Volumn 7, Issue 6, 2013, Pages 1411-1415

  Renard, Eric ^a,b   Cobelli, Claudio ^c   Zisser, Howard C ^d,e   Kovatchev, Boris P ^f  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^c UNIVERSITY OF PADOVA   (Italy)

^d SANSUM DIABETES RESEARCH INSTITUTE   (United States)

^e University of California   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Artificial pancreas; Closed loop insulin delivery; Continuous glucose monitoring; Control algorithm; Insulin pump

Indexed keywords

ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; DEVICE SAFETY; DIABETES MELLITUS; EDITORIAL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; OUTPATIENT CARE; PATIENT SAFETY; PATIENT SELECTION; PRODUCT DEVELOPMENT; SELF CARE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; HUMANS; INSULIN; OUTPATIENTS; PANCREAS, ARTIFICIAL; PATIENT SELECTION;

EID: 84900545219     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681300700601     Document Type: Editorial

References (10)

1. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765-74.
2. Langendam M, Luijf YM, Hooft L, Devries JH, Mudde AH, Scholten RJ. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2012;1:CD008101.
3. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes. 2011;60(11):2672-82.
4. ClinicalTrials.gov. Feasibility study using Zone-MPC controller, HMS and Technosphere ® Insulin Inhalation System from MannnKind Corp. http://www.clinicaltrials.gov/ct2/show/NCT01874392.
5. Lee JJ, Zisser H, Dassau E, Farret A, Place J, Pelletier MJ, Harvey RA, Doyle FJ III, Renard E. Clinical results of artificial pancreas using intraperitoneal insulin delivery. Diabetes. 2013;62(Suppl 1):A4-5.
6. Zisser H. Clinical hurdles and possible solutions in the implementation of closed-loop control in type 1 diabetes mellitus. J Diabetes Sci Technol. 2011;5(5):1283-6.
7. Breton M, Farret A, Bruttomesso D, Anderson S, Magni L, Patek S, Dalla Man C, Place J, Demartini S, Del Favero S, Toffanin C, Hughes-Karvetski C, Dassau E, Zisser H, Doyle FJ III, De Nicolao G, Avogaro A, Cobelli C, Renard E, Kovatchev B; International Artificial Pancreas Study Group. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes. 2012;61(9):2230-7.
8. Cobelli C, Renard E, Kovatchev BP, Keith-Hynes P, Ben Brahim N, Place J, Del Favero S, Breton MD, Farret A, Bruttomesso D, Dassau E, Zisser H, Doyle FJ III, Patek S, Avogaro A. Pilot studies of wearable artificial pancreas in type 1 diabetes. Diabetes Care 2012;35(9):e65-7.
9. Phillip M, Battelino T, Atlas E, Kordonouri O, Bratina N, Miller S, Biester T, Stefanija MA, Muller I, Nimri R, Danne T. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368(9):824-33.
10. Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes P, Anderson SM, Brown SA, Chernavvsky DR, Breton MD, Farret A, Pelletier MJ, Place J, Bruttomesso D, Del Favero S, Visentin R, Filippi A, Scotton R, Avogaro A, Doyle FJ III. Feasibility of outpatient fully integrated closedloop control: first studies of wearable artificial pancreas. Diabetes Care. 2013;36(7):1851-8.